These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16777619)

  • 21. Hematopoietic growth factors for hematopoietic stem cell mobilization and expansion.
    Möhle R; Kanz L
    Semin Hematol; 2007 Jul; 44(3):193-202. PubMed ID: 17631183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of hematopoietic growth factors in the treatment of neoplastic diseases.
    St Onge J; Jacobson RJ
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):53-63. PubMed ID: 1380737
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical use of hematopoietic growth factors].
    Robak T
    Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):365-8. PubMed ID: 1279638
    [No Abstract]   [Full Text] [Related]  

  • 24. [Hematopoietic growth factors in oncology and hematology. Recommendations for more cost-efficient use].
    Paul C; Hast R
    Lakartidningen; 2000 Jun; 97(23):2862-6. PubMed ID: 10885223
    [No Abstract]   [Full Text] [Related]  

  • 25. [Methods of autologous peripheral blood stem cell (PBSC) mobilization in oncological and hematological patients].
    Fregatova LM; Shavva SA; Platonova GG; Golovacheva AA; Afanas'ev BV
    Vopr Onkol; 1999; 45(4):380-3. PubMed ID: 10532095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re-evaluating the use of growth factors as adjuvant treatment of chronic hepatitis C.
    Worman HJ
    Hepatology; 2007 Oct; 46(4):1307-8; author reply 1307-8. PubMed ID: 17894319
    [No Abstract]   [Full Text] [Related]  

  • 28. [The use of erythropoietin alpha in programs of high-dose chemotherapy].
    Danova M; Aglietta M; Pierelli L; Ferrari S; Perillo A; Scambia G; Henry D
    Recenti Prog Med; 2000 Dec; 91(12):681-9. PubMed ID: 11194490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colony-stimulating factors: clinical promises.
    Koeffler HP
    Biotechnol Ther; 1989-1990; 1(2):181-92. PubMed ID: 2485242
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical use of hematopoietic growth factors].
    Krusius T
    Duodecim; 1990; 106(7):547-9. PubMed ID: 1727024
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hematopoietic growth factors. Current status of therapy].
    Hiddemann W
    Internist (Berl); 1994 Apr; 35(4):395-400. PubMed ID: 7515381
    [No Abstract]   [Full Text] [Related]  

  • 32. [Hematopoietic growth factors in antineoplastic therapy from the therapeutic and economic aspect].
    Adam Z; Vorlícek J; Tomíska M
    Vnitr Lek; 1993 May; 39(5):487-500. PubMed ID: 7688919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes.
    Ganser A; Hoelzer D
    Semin Hematol; 1996 Jul; 33(3):186-95. PubMed ID: 8819229
    [No Abstract]   [Full Text] [Related]  

  • 34. Hematopoietic growth factors for the treatment of inherited cytopenias.
    Zeidler C; Welte K
    Semin Hematol; 2007 Jul; 44(3):133-7. PubMed ID: 17631177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of myelodysplastic syndromes with hematopoietic growth factors.
    Ganser A; Hoelzer D
    Hematol Oncol Clin North Am; 1992 Jun; 6(3):633-53. PubMed ID: 1377194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Rossi Ferrini P; Santini V; Ciolli S; Grossi A; Leoni F; Rafanelli D; Vannucchi AM
    Hematol Oncol; 1993; 11 Suppl 1():32-5. PubMed ID: 7683622
    [No Abstract]   [Full Text] [Related]  

  • 37. Myeloid growth factors as anti-infective measures in children with leukemia and lymphoma.
    Lehrnbecher T; Creutzig U
    Expert Rev Hematol; 2009 Apr; 2(2):159-72. PubMed ID: 21083449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic growth factors--present status and future development.
    Ganser A
    Semin Hematol; 2007 Jul; 44(3):131-2. PubMed ID: 17631176
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Towards improved cancer therapy using subcutaneously administered hemopoietic colony stimulating factors.
    Morstyn G; Sheridan W; Lieschke G; Cebon J; Layton J; Fox R
    Prog Clin Biol Res; 1990; 354B():29-36. PubMed ID: 1700441
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.